ProfileGDS5678 / 1430400_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 48% 48% 46% 48% 50% 50% 47% 46% 47% 50% 48% 48% 48% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2093349
GSM967853U87-EV human glioblastoma xenograft - Control 23.1325148
GSM967854U87-EV human glioblastoma xenograft - Control 33.1357848
GSM967855U87-EV human glioblastoma xenograft - Control 43.0336346
GSM967856U87-EV human glioblastoma xenograft - Control 53.0772448
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3078850
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2778650
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1050847
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0691846
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0921647
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1907350
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1052448
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.155448
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.123248